Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365599 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00365599 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 43 participants.
The verdict
NCT00365599, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
Interventions
- DRUG suberoylanilide hydroxamic acid (SAHA, Vorinostat)
- DRUG tamoxifen citrate (Tamoxifen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365599
The ClinicalTrials.gov registry entry for NCT00365599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which suberoylanilide hydroxamic acid (SAHA, Vorinostat) is the first listed.
NCT00365599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365599 about?
NCT00365599 is a clinical study titled "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer". Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
What is the current status of trial NCT00365599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2006-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00365599?
The interventions under investigation include: suberoylanilide hydroxamic acid (SAHA, Vorinostat) (DRUG), tamoxifen citrate (Tamoxifen) (DRUG).
Who is sponsoring clinical trial NCT00365599?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.